4880 Stock Overview
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CellSource Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,517.00 |
| 52 Week High | JP¥3,180.00 |
| 52 Week Low | JP¥1,179.00 |
| Beta | 0.25 |
| 1 Month Change | 2.36% |
| 3 Month Change | 22.54% |
| 1 Year Change | -41.81% |
| 3 Year Change | -63.85% |
| 5 Year Change | n/a |
| Change since IPO | 94.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4880 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | -2.2% | 1.0% | 1.8% |
| 1Y | -41.8% | -34.1% | 31.0% |
Return vs Industry: 4880 underperformed the JP Life Sciences industry which returned -34.1% over the past year.
Return vs Market: 4880 underperformed the JP Market which returned 31% over the past year.
Price Volatility
| 4880 volatility | |
|---|---|
| 4880 Average Weekly Movement | 7.5% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4880 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4880's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 151 | Takashi Sawada | www.cellsource.co.jp |
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients’ adipose tissues, and to prepare platelet-rich plasma from patients’ blood; and offers support services for medical facilities providing regenerative medicine therapy, as well as manufacturing processed cells. It is also involved in the development and sale of Signalift series of anti-aging products, including a serum.
CellSource Co., Ltd. Fundamentals Summary
| 4880 fundamental statistics | |
|---|---|
| Market cap | JP¥30.04b |
| Earnings (TTM) | JP¥850.00m |
| Revenue (TTM) | JP¥4.62b |
35.3x
P/E Ratio6.5x
P/S RatioIs 4880 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4880 income statement (TTM) | |
|---|---|
| Revenue | JP¥4.62b |
| Cost of Revenue | JP¥1.46b |
| Gross Profit | JP¥3.17b |
| Other Expenses | JP¥2.32b |
| Earnings | JP¥850.00m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
Jun 13, 2024
| Earnings per share (EPS) | 42.92 |
| Gross Margin | 68.51% |
| Net Profit Margin | 18.38% |
| Debt/Equity Ratio | 0% |
How did 4880 perform over the long term?
See historical performance and comparison